Multiple studies have highlighted the strong therapeutic potential of the combination of MEK and PI3KCA inhibitors [33, 34], using CRC 3D models [30, 35], however, very few validated this combination strategy directly in CRC PDOs. Here, MAP2K7 is linked to colorectal carcinoma.